Efficacy and safety of probiotics in treatment of patients with mild cognitive impairment and Alzheimer's disease
武琰娇 1陈丽萍 1侯怀晶 1徐紫清 1张凌云1
扫码查看
点击上方二维码区域，可以放大扫码查看
作者信息
1. 甘肃省中医院麻醉科,兰州 730050;甘肃省中医院麻醉疼痛医学中心,兰州 730050
折叠
摘要
目的 探讨益生菌增补治疗轻度认知障碍(MCI)和阿尔茨海默病(AD)患者的有效性及安全性.方法 检索PubMed、Cochrane Library、Web of Science、Embase、中国生物医学文献数据库、知网、维普及万方数据库,搜集所有关于益生菌增补治疗AD及MCI患者有效性及安全性的研究,时间从建库至2022年12月.由2位评价员独立筛选文献、提取资料并评价纳入研究的偏倚风险后,采用RevMan 5.3软件进行meta分析.结果 共纳入10个研究,716例患者.meta分析结果显示:益生菌组在提高简易智力状态检查量表(MMSE)积分(MD=1.23,95％CI 0.18～2.27,P=0.02)方面优于对照组,差异有统计学意义;两组不良反应发生率差异无统计学意义(OR=0.63,95％CI0.25～1.63,P=0.34).结论 益生菌增补治疗在改善MCI和AD患者认知功能效果方面具有积极作用,且具有良好的安全性.
Abstract
Objective To explore the efficacy and safety of probiotics in the treatment of patients with mild cognitive impairment(MCI)and Alzheimer's disease(AD).Methods The PubMed,Cochrane Library,EMbase,China National Knowledge Infrastructure,Database for Chinese Technical Periodicals,WanFang Data,and China Biology Medicine disc were searched to collect the studies on the efficacy and safety of probiotics in the treatment of patients with MCI and AD from their establishment to November,2022.Two reviewers independently screened the literatures,extracted the data,and assessed the risk of bias of the included studies.Meta-analysis was performed using the RevMan 5.4.1 software.Results A total of 10 studies involving 716 patients were included.The results of the meta-analysis showed that the Mini-Mental State Examination score of the probiotic group was better than that of the control group(MD=1.23,95％CI 0.18-2.27,P=0.02).There was no statistical difference in the incidence of adverse reactions between the two groups(OR=0.63,95％CI 0.25-1.63,P=0.34).Conclusion Probiotics have positive effectiveness in improving the cognitive function of patients with MCI and AD,with satisfactory safety.
维普
万方数据